Clearside Biomedical (NSDQ:CLSD) has agreed to grant Regenxbio (NSDQ:RGNX) the option to an exclusive worldwide license to sell Clearside’s SCS gene therapy microinjector.
The option and licensing deal is potentially worth more than $130 million, the companies said.
Get the full story on our sister site, Drug Delivery Business News.